Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before Upcoming Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aquestive Therapeutics, Inc. for investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave a false impression about the approval of its New Drug Application for Anaphylm, leading to a significant stock price drop after deficiencies were identified by the FDA. Investors who suffered losses have until May 4, 2026, to apply for lead plaintiff in the lawsuit.
How this was made

The 30-second read
Why it matters
Legal action and FDA deficiencies have created negative investor sentiment, impacting stock valuation.
Market read
Legal and regulatory issues are significant catalysts affecting AQST's stock, with potential ripple effects in the biotech sector.
What to watch
Potential pipeline advancements or upcoming catalysts not mentioned in the news could offset legal risks.
Background
The lawsuit alleges misrepresentation regarding FDA approval of a key drug, leading to a stock price drop.
Ticker impact
High relevance due to recent legal action and negative sentiment.
Potential further decline in stock price by 5-10% in the near term.
Legal issues and FDA setbacks typically lead to investor pessimism and stock price drops, especially with a bearish sentiment score of -0.60.
Market effects
Potential negative impact on biotech and life sciences sectors due to legal and regulatory concerns.
Limited regional impact; primarily affects US-based biotech stocks.
Moderate, as FDA decisions influence global biotech investor sentiment.
Counterpoint
If the lawsuit leads to a settlement or positive legal outcome, AQST could recover, presenting a buying opportunity.
Key entities
- Law FirmBragar Eagel & Squire, P.C.
Legal firm initiating class action lawsuit against AQST.
- Biotech CompanyAquestive Therapeutics, Inc.
Target of the lawsuit due to alleged false impressions about drug approval.





